Related Experiment Video
Updated: Aug 15, 2026

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography
Published on: August 12, 2022
C-type natriuretic peptide relaxes human coronary artery bypass grafts preconstricted by endothelin-1
Christopher J Kelsall1, Adrian H Chester, Mohammed Amrani
1Department of Cardiothoracic Surgery, Heart Science Centre and Harefield Hospital, Harefield, Middlesex, United Kingdom. c.kelsall@imperial.ac.uk
Insights
C-type natriuretic peptide effectively reverses endothelin-induced graft vasospasm in vessels used for coronary artery bypass surgery. This finding highlights its therapeutic potential for preventing post-operative graft dysfunction.
Area of Science:
- Vascular Biology
- Pharmacology
- Cardiovascular Surgery
Background:
- Endothelin contributes to graft spasm following coronary artery bypass grafting (CABG).
- Investigating endothelium-derived vasodilators for reversing this spasm is crucial.
Purpose of the Study:
- To assess the efficacy of C-type natriuretic peptide (CNP) in reversing endothelin-induced contractions.
- To compare CNP's effects with other vasodilators in common CABG conduits.
Main Methods:
- Human radial artery, saphenous vein, and internal mammary artery segments were studied.
- Vessel contractions induced by endothelin were measured in organ baths.
- Relaxation responses to CNP, acetylcholine, sodium nitroprusside, and papaverine were evaluated.
Main Results:
- CNP significantly relaxed endothelin-precontracted vessels, particularly the radial artery (66% relaxation).
- Aprotinin did not alter CNP-mediated relaxation.
- Acetylcholine and papaverine also induced relaxation, but CNP demonstrated potent effects.
Conclusions:
- CNP effectively reverses endothelin-induced vasoconstriction in arterial and venous grafts.
- CNP shows significant therapeutic potential for preventing graft vasospasm post-CABG.
- In vitro enzymatic degradation of CNP appears minimal, supporting its stability.
Background:
Endothelin is implicated in graft spasm after coronary artery bypass grafting. We assessed reversal by the endothelium-derived vasodilator C-type natriuretic peptide of prior contraction of radial artery and other vessels commonly used for coronary artery bypass surgery.
Methods:
Segments of human radial artery, saphenous vein, and internal mammary artery were mounted in organ baths after removal from patients undergoing cardiac surgery (n = 34; 64 +/- 2 years). Effects of increasing concentrations of C-type natriuretic peptide (with or without aprotinin, 1,000 U/mL) on endothelin-induced contraction were compared with acetylcholine, sodium nitroprusside, and papaverine.
Results:
C-type natriuretic peptide relaxed endothelin precontraction in all vessels (F = 17.8, 36.3, and 48.4, respectively; p < 0.001), with maximum relaxations of 44%, 54%, and 66% in saphenous vein, internal mammary artery, and radial artery, respectively. Aprotinin did not affect relaxation to C-type natriuretic peptide. Acetylcholine relaxed the saphenous vein weakly, with maximal relaxation of 9% at 10(-6) M. However, the radial artery and internal mammary artery relaxed strongly to acetylcholine. The highest concentration of papaverine completely relaxed all vessels, but responses were less sensitive than to sodium nitroprusside or acetylcholine.
Conclusions:
C-type natriuretic peptide reverses endothelin-induced constriction in arterial and venous conduits used for coronary artery bypass, particularly the radial artery. Proteolytic breakdown of C-type natriuretic peptide by local vascular enzymes appears of little importance in vitro. This signals the therapeutic potential of using C-type natriuretic peptide as an antagonist of graft vasospasm after coronary artery bypass surgery.
Related Concept Videos
Nitric Oxide Signaling Pathway
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

